Traders should monitor the ASCO presentation on June 1, 2026, for safety and dosimetry signals that could de-risk the broader ProstACT Global trial and boost confidence in TLX591-Tx’s differentiation. Positive data could catalyze re-rating ahead of Part 2 readout.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $10.33entry
- T+1 · 7mo ago −1.36%α −0.96% · $10.19
- T+5 · 7mo ago +1.06%α +1.01% · $10.44
- T+20 · 6mo ago −1.55%α −4.71% · $10.17
- T+60 · 4mo ago +1.26%α −3.52% · $10.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT Global trial for TLX591-Tx will be presented as a late-breaking oral presentation at the 2026 ASCO Annual Meeting. The selection for a high-profile session underscores the potential clinical relevance of its radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
Key Facts
- Safety and dosimetry data from Part 1 of the ProstACT Global Phase 3 trial will be presented at ASCO 2026 as a late-breaking oral presentation.
- Part 1 included 36 patients and assessed tolerability, biodistribution, and radiation dose profile of TLX591-Tx in combination with standard of care.
- TLX591-Tx shows reduced kidney toxicity and minimal salivary/lacrimal gland uptake compared to other PSMA-targeted therapies.
- The abstract was selected for a high-visibility session at ASCO, indicating strong interest from the oncology community.
Financial Impact
Potential long-term commercial upside due to favorable safety profile and high-visibility data readout, though no immediate revenue impact.
Risk Factors
- TLX591-Tx remains investigational and has not received marketing authorization.
- Part 1 data are preliminary and from a small cohort; efficacy results from the larger Part 2 are still pending.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278510 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers